<DOC>
	<DOCNO>NCT00094094</DOCNO>
	<brief_summary>This Phase 2 study conduct multiple center United States Germany . Patients non-small cell lung cancer spread part body ( i.e. , metastatic ) locally advanced ( i.e. , Stage IIIB malignant pleural effusion ) eligible participate . Patients must disease treat least 1 prior treatment metastatic disease ( prior adjuvant treatment localize disease count prior treatment metastatic disease ) . The purpose study test whether angiogenesis inhibitor AG-013736 effective treatment advance non-small cell lung cancer show number patient study experience significant durable tumor shrinkage</brief_summary>
	<brief_title>Anti-angiogenesis Agent AG-013736 Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Histologically document nonsmall cell lung cancer metastasis ( Stage IV recurrent disease ) locally advanced ( Stage IIIB ) malignant pleural effusion . At least 1 prior systemic therapy metastatic disease ( Prior adjuvant therapy localize disease count prior therapy metastatic disease ) . Central lung lesion involve major blood vessel ( artery vein ) . ( Central lesion maintain structural integrity vessel potential bleed tumor lesion undergoes necrosis . MRI CT angiography use case question whether blood vessel involve . ) Patients history Grade 2 bad hemoptysis eligible . Patients history Grade 1 hemoptysis within 30 day entry eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>